TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00298831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
Study: NCT00688766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retaspimycin hydrochloride (IPI-504)
Description: IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
Study: NCT04419116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tibial preservation bone cut
Description: tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tibial preservation bone cut
Description: tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
Study: NCT04587193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assist gait training device
Description: PD participants will walk while wearing a robotic-assist gait training device
Study: NCT01720069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler device
Study: NCT03707288

Intervention type: OTHER
Group type: OTHER
Intervention: Spine Exercise Program
Description: Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
Study: NCT04615559

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
Study: NCT04069208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin and cytarabine induction
Description: Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
Study: NCT00379470

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A
Description: multiple four-week courses of continuous NovoTTF-100A treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A
Description: multiple four-week courses of continuous NovoTTF-100A treatment
Study: NCT03676361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
Study: NCT00411619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
Study: NCT03591575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Liquid formulation of deferiprone, with a concentration of 80 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid solution that matches deferiprone oral solution in appearance and taste
Study: NCT02265393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02120638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide containing regimen
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
Study: NCT01521507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow System
Description: In-office device treatment for meibomian gland dysfunction by a physician

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow System
Description: In-office device treatment for meibomian gland dysfunction by a physician
Study: NCT03692767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD22 CAR NK Cells
Description: Anti-CD22 CAR NK Cells injection
Study: NCT02469402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin
Study: NCT02120638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen without Pyrazinamide
Description: Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
Study: NCT04045769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4mg
Description: 1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5 tablets of placebo to be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 1 tablet of 400 mg Moxifloxacin to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 20 mg
Description: 5 tablets of 4 mg Saroglitazar magnesium to be administered orally
Study: NCT00595621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)
Description: Multi-Channel Phased Gastric Pacemaker (MGP-1)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)
Description: Multi-Channel Phased Gastric Pacemaker (MGP-1)
Study: NCT03412721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser analgesic procedure
Description: Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo analgesic procedure
Description: Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
Study: NCT04885309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Stimulator-guided Obturator Nerve Block
Description: Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Nerve Stimulator-guided Obturator Nerve Block
Description: Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
Study: NCT01521507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Compress Therapy + Lid Scrub
Description: At-home daily warm compress therapy and lid hygiene
Study: NCT02153866

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rotavirus vaccine
Description: 3ml/dose, oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine
Description: 3ml/dose, oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rotavirus vaccine
Description: 3ml/dose, oral

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: measles-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: measles-mumps-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles-mumps-rubella vaccine
Description: 0.5ml per dose, subcutaneous injection
Study: NCT03739710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feladilimab
Description: Feladilimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4428859A
Description: GSK4428859A/EOS884448 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4428859A
Description: GSK4428859A/EOS884448 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK6097608
Description: GSK6097608 will be administered.
Study: NCT02316704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 PPS coted acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 PPS coted acetabular component
Study: NCT01969006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine ½%

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Needle prick
Study: NCT02545608

Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Vital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Study: NCT03694717

Intervention type: DRUG
Intervention: Saline Solution for Injection
Description: The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
Study: NCT03275740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 intravenous healthy participant
Description: Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous healthy participant
Description: Placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 subcutaneous healthy participant
Description: single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.
Study: NCT02316704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 PPS coted acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 PPS coted acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 OsseoTi coted acetabular component
Study: NCT03275740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous healthy participant
Description: placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06755347 subcutaneous ITP
Description: single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants
Study: NCT02731495

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG
Description: EGCG (Epigallocatechin -3-gallate)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (deionized water)
Study: NCT01290614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist based QI program
Description: Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR \<30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the control arm will continue to receive usual care from their VA providers.
Study: NCT02316704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 OsseoTi coted acetabular component
Study: NCT01358825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: A blood sample will be taken at 5 years of age, after vaccination in the primary study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: A blood sample will be taken at 5 years of age, after vaccination in the primary study.
Study: NCT01153737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Description: Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
Study: NCT00509470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan plus hydrochlorothiazide
Description: Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study: NCT03104179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb Adsorber
Description: Cytokine adsorption during CPB
Study: NCT03641040

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video-oculography
Description: measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Alternative prism cover test
Description: measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
Study: NCT04079595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Head immobilization mask
Description: Immobilization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head immobilization mask
Description: Immobilization
Study: NCT02564458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval Exercise Training/Motivational Accelerometry
Description: During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
Study: NCT05441631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: * Preparation: 50 IU of rapidly acting insulin in 50 ml of 0.9% saline solution was delivered through a 50-ml syringe-driven pump.~* Monitoring: The insulin dose was adjusted to whole-blood glucose levels using glucometer every hour and insulin infusion was continued till BG level (Targeted level) was 80-110 mg, and then BG levels were estimated four-hourly~* Insulin dose was titrated according to the Leuven titration protocol (15)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: * Insulin dose was titrated according to the Blood glucose level~* monitoring according to glucose in urine
Study: NCT01814475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: Fludarabine + Busulphan
Description: Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Fludarabine + Thiotepa
Description: Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
Study: NCT01463241

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral and Affective Skills in Coping (BASIC)
Description: The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills \[Belief Repair, Action, Solving Problems, Incentives, and Calming\]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
Study: NCT04317040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Efprezimod alfa is given on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given on Day 1.
Study: NCT03266133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education for Pregnancy
Description: Sleep education specific to pregnancy